Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

PPBT

Purple Biotech Ltd ADR

Dec 13 • 04:00PM ET

3.83

Dollar change +0.17
Percentage change 4.64	%

Healthcare • Biotechnology • Israel • NASD

Peers: AMRN ADAP CRDF GNFT RDUS DVAX AFMD ONCT ATNM APVO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-8.94	Insider Own	0.75%	Shs Outstand	2.58M	Perf Week	-18.34%
Market Cap	9.88M	Forward P/E	-	EPS next Y	-1.65	Insider Trans	0.00%	Shs Float	2.56M	Perf Month	43.98%
Income	-11.66M	PEG	-	EPS next Q	-0.22	Inst Own	6.60%	Short Float	2.75%	Perf Quarter	-52.24%
Sales	0.00M	P/S	-	EPS this Y	95.39%	Inst Trans	-	Short Ratio	0.08	Perf Half Y	-68.14%
Book/sh	16.90	P/B	0.23	EPS next Y	-98.80%	ROA	-29.01%	Short Interest	0.07M	Perf Year	-78.09%
Cash/sh	2.44	P/C	1.57	EPS next 5Y	-	ROE	-34.28%	52W Range	2.00 - 20.60	Perf YTD	-75.45%
Dividend Est.	-	P/FCF	-	EPS past 5Y	26.09%	ROI	-39.59%	52W High	-81.41%	Beta	1.10
Dividend TTM	-	Quick Ratio	1.27	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	91.50%	ATR (14)	1.10
Dividend Ex-Date	-	Current Ratio	1.27	EPS Y/Y TTM	56.99%	Oper. Margin	-	RSI (14)	49.36	Volatility	13.29% 29.43%
Employees	20	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	33.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	91.88%	Payout	-	Rel Volume	0.10	Prev Close	3.66
Sales Surprise	-	EPS Surprise	67.50%	Sales Q/Q	-	Earnings	Nov 15 BMO	Avg Volume	888.30K	Price	3.83
SMA20	1.81%	SMA50	3.05%	SMA200	-55.18%	Trades		Volume	88,009	Change	4.64%

Dec-05-24 07:13AM	Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares (GlobeNewswire) -16.93%
Dec-03-24 08:23AM	Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares (GlobeNewswire) -21.79%
Dec-02-24 07:00AM	Purple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic Cancer (GlobeNewswire) +150.37%
Nov-15-24 07:00AM	Purple Biotech Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 08:13AM	Purple Biotech Unveils Promising Biomarker for Cancer Therapy (TipRanks)
07:50AM	Loading…
Nov-04-24 07:50AM	Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death (GlobeNewswire)
Oct-25-24 07:20AM	Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -9.35%
Oct-11-24 07:57AM	Purple Biotech Unveils CAPTN-3 Cancer Therapy (TipRanks)
Oct-10-24 07:30AM	Purple Biotech to Present Data for its Tri-Specific Antibody Platform CAPTN-3 at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-18-24 06:30AM	Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24 (GlobeNewswire)
Sep-16-24 09:38AM	Upcoming Stock Splits This Week (September 16 to September 20) Stay Invested (TipRanks)
Sep-10-24 07:00AM	Purple Biotech to Present Data for its Lead Oncology Drug CM24 at the AACR Special Conference on Advances in Pancreatic Cancer Research (GlobeNewswire)
Aug-30-24 07:00AM	Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +6.30%
Aug-16-24 10:53PM	PPBT Stock Earnings: Purple Biotech Beats EPS for Q2 2024 (InvestorPlace)
08:12AM	Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights (GlobeNewswire)
07:35AM	Loading…
Jul-25-24 07:35AM	Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule (GlobeNewswire)
Jul-10-24 07:30AM	Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024 (GlobeNewswire) +15.31%
Jul-02-24 04:00PM	Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds (GlobeNewswire)
Jul-01-24 09:00AM	Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds (GlobeNewswire) -11.77%
Jun-27-24 07:45AM	Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit (GlobeNewswire) -8.83%
Jun-01-24 08:00AM	Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer (GlobeNewswire)
May-21-24 01:52PM	PPBT Stock Earnings: Purple Biotech Beats EPS for Q1 2024 (InvestorPlace) +6.54%
07:30AM	Purple Biotech Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-25-24 07:00AM	Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting (GlobeNewswire)
Mar-28-24 07:00AM	Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 (GlobeNewswire) +9.66%
Mar-14-24 07:30AM	Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology (GlobeNewswire)
Mar-13-24 09:55AM	Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher (Zacks)
Mar-05-24 11:52PM	PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023 (InvestorPlace)
07:55AM	Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 07:00AM	Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024 (GlobeNewswire) -5.91%
07:00AM	Loading…
Feb-13-24 07:00AM	Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial (GlobeNewswire)
Feb-01-24 07:30AM	Purple Biotech Reaches Recommended Phase 2 Dose for NT219 (GlobeNewswire)
Dec-20-23 08:05AM	Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors (GlobeNewswire) -9.17%
Dec-14-23 06:50AM	Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial (GlobeNewswire)
Nov-21-23 06:50AM	Purple Biotech Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 07:00AM	Purple Biotech Fortifies NT219 Patent Protection (GlobeNewswire)
Oct-19-23 03:55PM	Purple Biotech Announces Closing of $5 Million Registered Direct Offering (GlobeNewswire) +13.04%
Oct-17-23 08:00AM	Purple Biotech Announces $5 Million Registered Direct Offering (GlobeNewswire)
Oct-06-23 07:50AM	Purple Biotech Reports Potential Biomarker Data Support CM24s Mechanism of Action (GlobeNewswire)
Oct-03-23 07:50AM	Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer (GlobeNewswire) -8.18%
Sep-21-23 08:00AM	Purple Biotech to Present New CM24 Pancreatic Cancer Biomarker Data at AACR Special Conference on September 28, 2023 (GlobeNewswire) +8.82%
Aug-22-23 09:29AM	Purple Biotech Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-11-23 08:15AM	Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients (GlobeNewswire) -7.72%
May-16-23 04:00PM	Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-25-23 08:00AM	Purple Biotech Debuts Scientific Advisory Board (GlobeNewswire)
Apr-19-23 08:15AM	Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors (GlobeNewswire)
Apr-18-23 07:00AM	Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference (GlobeNewswire)
Mar-24-23 07:00AM	Purple Biotech Reports Temporary Medical Leave of CEO Gil Efron (GlobeNewswire) -5.11%
Mar-16-23 07:00AM	Purple Biotech Reports Biomarker Data from CM24 Phase 1 Dose Escalation Study (GlobeNewswire)
Feb-14-23 07:01AM	Purple Biotech Announces First Patient Dosed in Open Label, Randomized Part of CM24 Phase 2 Clinical Trial (GlobeNewswire) +6.68%
Feb-08-23 07:12AM	Purple Biotech Reports Fourth Quarter and Full-Year 2022 Financial Results (GlobeNewswire)
Feb-02-23 07:00AM	Purple Biotech Expands Pipeline of First-in-Class Therapeutics with Acquisition of Immunorizon and Its Portfolio of Tri-Specific Antibodies for the Treatment of Cancer (GlobeNewswire) +6.18%
Jan-03-23 07:00AM	Purple Biotech and Mor Research Applications Announce Research Collaboration to Identify Promising Investigational Oncology Treatments (GlobeNewswire)
Nov-15-22 07:00AM	Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis (GlobeNewswire) +5.37%
Nov-10-22 07:00AM	Purple Biotech to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-08-22 07:53AM	Purple Biotech Reports Third Quarter 2022 Financial Results (GlobeNewswire) -5.63%
Nov-02-22 07:37AM	Purple Biotech Appoints Lior Fhima as Chief Financial Officer (GlobeNewswire)
Aug-04-22 07:30AM	Purple Biotech Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-14-22 07:30AM	Purple Biotech Announces Executive Leadership Changes (GlobeNewswire)
May-27-22 07:15AM	Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile (GlobeNewswire) -6.21%
May-18-22 08:18AM	Purple Biotech Announces the Initiation of Phase 2 Study for CM24 in 2L PDAC Patients (GlobeNewswire) +7.02%
May-12-22 08:13AM	Purple Biotech Reports First Quarter 2022 Financial Results (GlobeNewswire) -6.80%
Apr-11-22 07:37AM	Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting (GlobeNewswire) -29.97%
Feb-24-22 12:12AM	Could The Solid State plc (LON:SOLI) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Feb-09-22 07:00AM	Purple Biotech Reports Second Half and Full-Year 2021 Financial Results (GlobeNewswire)
Feb-04-22 07:35AM	Purple Biotech Issues Letter to Shareholders (GlobeNewswire) +6.12%
Jan-06-22 07:30AM	Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors (GlobeNewswire)
07:24AM	Is Solid State plc's(LON:SOLI) Recent Stock Performance Tethered To Its Strong Fundamentals? (Simply Wall St.)
Dec-09-21 07:30AM	Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer (GlobeNewswire)
03:30AM	Is Now An Opportune Moment To Examine Solid State plc (LON:SOLI)? (Simply Wall St.)
Dec-06-21 07:30AM	Purple Biotech Announces Initiation of Part 2 of Ongoing Phase 1/2 Clinical Trial Evaluating NT219 for Treatment of Multiple Cancers Supporting Potential Expansion of Clinical Program (GlobeNewswire) +6.40%
Nov-03-21 07:30AM	Purple Biotech to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-26-21 08:27AM	Purple Biotech Expands Research Collaboration in Immuno-Oncology in Combination with NT219 (GlobeNewswire)
Oct-22-21 06:00AM	Purple Biotech Announces Publication in Nature Cancer Demonstrating Mechanisms Behind Cancer Cell Persistence Frequency and Potential of NT219 to Reduce Therapeutic Resistance (GlobeNewswire)
Sep-24-21 07:38AM	We Think Solid State (LON:SOLI) Can Stay On Top Of Its Debt (Simply Wall St.)
Sep-13-21 07:00AM	Purple Biotech to Present Overview of Ongoing Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers at ESMO 2021 and Provides Clinical Update (GlobeNewswire)
Aug-05-21 08:30AM	Purple Biotech Provides Corporate Update and Reports First Half 2021 Financial Results (GlobeNewswire)
Jun-04-21 08:00AM	Purple Biotech Presents New Clinical Data from NT219 at the 2021 ASCO Annual Meeting (GlobeNewswire) -11.76%
May-26-21 07:38AM	Purple Biotech to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-20-21 07:00AM	Purple Biotech to Present New Clinical Data from NT219 at the 2021 ASCO Annual Meeting (GlobeNewswire) +8.21%
May-19-21 07:00AM	Purple Biotech Appoints Seasoned Biopharmaceutical Industry Executive Suzana Nahum-Zilberberg to Board of Directors (GlobeNewswire)
Apr-23-21 08:00AM	Purple Biotech Announces Dosing of First Patient in Phase 1b/2 Clinical Trial of CM24 in Advanced Cancer Patients (GlobeNewswire)
Apr-13-21 08:17AM	Purple Biotech Presents Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting (GlobeNewswire)
Mar-19-21 08:00AM	Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers (GlobeNewswire)
Mar-11-21 08:02AM	Purple Biotech to Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting (GlobeNewswire)
Mar-03-21 07:00AM	Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors (GlobeNewswire)
Mar-02-21 07:00AM	Purple Biotech Provides Corporate Update and Reports Second Half and Full Year 2020 Financial Results (GlobeNewswire) -6.32%
Jan-18-21 07:41AM	Purple Biotech to Present at the B. Riley Oncology Investor Conference (GlobeNewswire)
Jan-04-21 09:40AM	Purple Biotech to Ring the Nasdaq Stock Market Opening Bell (GlobeNewswire) +6.56%

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. It operates through two segments: Oncology, and Pain & Hypertension. The Oncology segment includes NT219, a therapeutic candidate which is a small molecule that targets two signal transduction pathways which are involved in the development of cancer drug resistance mechanisms, and which is currently in the late pre-clinical stage of development. The Pain & Hypertension segment includes Consensi, a combination drug for the simultaneous treatment of two clinical conditions, pain caused by osteoarthritis and hypertension (high blood pressure), which can be pre-existing or caused by the treatment for osteoarthritis. The company was founded by John Paul Waymack on August 12, 1968 and is headquartered in Rehovot, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PPBT

Purple Biotech Ltd ADR

Upgrade your FINVIZ experience